GSK Q2 sales beat analyst estimates on specialty medicines growth
GSK Q2 sales beat analyst estimates on specialty medicines growth
Overview
UK pharma and vaccines firm's Q2 sales rose 5%, beating analyst expectations
Adjusted EPS and operating profit for Q2 beat analyst expectations
Company completed £2 bln share buyback and declared 17p Q2 dividend
Outlook
GSK reaffirms 2026 guidance: turnover to grow 3% to 5% at CER
Company expects core operating profit to grow 7% to 9% at CER in 2026
Vaccines turnover outlook raised to stable or low single-digit growth for 2026
Result Drivers
SPECIALTY MEDICINES GROWTH - Double-digit sales growth in Specialty Medicines, driven by strong demand in HIV (notably long-acting injectables), Oncology, and RI&I products such as Nucala and Benlysta
VACCINES PERFORMANCE - Vaccines sales rose 8%, with growth led by Arexvy, Meningitis vaccines, and Shingrix, though Shingrix growth was partly offset by lower demand in some regions
PRODUCT AND REGIONAL MIX - Core operating profit and EPS benefited from higher sales and favourable product and regional mix, partly offset by increased R&D investment and lower royalty income
Company press release: ID:nRSb1486Oa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Sales | Beat | GBP 8.41 bln | GBP 8.24 bln (7 Analysts) |
Q2 Adjusted EPS | Beat | GBP 0.51 | GBP 0.46 (7 Analysts) |
Q2 Adjusted Operating Profit | Beat | GBP 2.80 bln | GBP 2.65 bln (7 Analysts) |
Q2 Dividend |
| GBP 0.17 |
|
Q2 Free Cash Flow |
| GBP 2 bln |
|
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 7 "strong buy" or "buy", 14 "hold" and 3 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for GSK plc is GBp2,060.00, about 5% above its July 27 closing price of GBp1,961.00
The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 11 three months ago
Reuters Recommended Reads
July 28 - GSK to invest £400 million in Britain over 3 years as it ramps up R&D efforts
July 28 - GSK, Hansoh's bone cancer drug meets main goal in late-stage trial
July 27 - AstraZeneca profit beat, bullish tone ease worries over drug pipeline
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)